Current stock page

Stock Analysis

Viking Therapeutics, Inc. (VKTX) Stock Analysis

Viking Therapeutics, Inc. (VKTX) stock analysis covering valuation, fundamentals, technical indicators, risk, AIQ Momentum, analyst catalysts, dividends, and the current AIQ Score.

VKTX Stock Analysis Summary

Viking Therapeutics, Inc. (VKTX) currently has an AIQ Score of 41/100, indicating a bearish setup. Momentum is the strongest factor at 47/100. Quality is the weakest current factor at 33/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.

Updated Nov 13, 2026 · Market-close data

VKTX at a Glance

Crawlable current metrics from the latest market-close stock snapshot.

MetricCurrent
Price$29.22
AIQ Score41/100
Overall ViewBearish
Technical Analysis ConsensusBuy
Market Cap$3.45B
P/E Ratio (TTM)-5.41
Forward P/E—
EPS (Q3 FY2026)-$1.55
Revenue (Q3 FY2026)$0
Dividend Yield (TTM)0.00%
Beta1.29
Volume8.87M
52-week range$23.82-$43.10
RSI 1454.98
50-Day SMA$29.33
200-Day SMA$32.17
Analyst Price Target$79.67
Next EarningsFeb 10, 2027
As of Nov 13, 2026 · Market close

VKTXViking Therapeutics, Inc.

Healthcare / Biotechnology

Low Priority

Above Peers

BearishEdge 7/10
$29.22+$1.64 (+5.95%)

Latest quote

  • Momentum
    47
  • Value
    —
  • Quality
    33
  • Risk resilience
    41
  • Sentiment
    —
algovestiq.comScore data as of Nov 13, 2026

VKTX Stock Analysis Summary

Viking Therapeutics, Inc. (VKTX) currently has an AIQ Score of 41/100, indicating a bearish setup. Momentum is the strongest factor at 47/100. Quality is the weakest current factor at 33/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.

Updated Nov 13, 2026 · Market-close data
AIQ Composite Posture: Bearish

In a bearish regime, VKTX has AIQ Score of 41/100 with Momentum base of 47/100 and fading Quality at 33/100. Wait for component alignment before adding exposure.

Healthcare · 5.95% stock move · VKTX classified in Biotechnology.

Current Evidence

BearishVKTX is in a bearish AIQ regime; Momentum is the strongest visible factor at 47/100.
Core coverage reflects visible evidence only

AlgovestIQ Evidence Summary

Current consensus, supporting evidence, recent changes, and what would strengthen or weaken the view.

Is VKTX Bullish or Bearish Right Now?

VKTX currently has a bearish overall setup. Momentum is the strongest factor at 47/100, while Quality is weakest at 33/100. The current evidence suggests a bearish setup.

Bull Case
  • - Analyst target implies +172.64% upside from the latest quote.
  • - Technical consensus has more buy votes than sell votes (29 vs 12).
Bear Case
  • - Momentum is weak at 47/100.
  • - Risk Resilience is weak at 41/100.
  • - Price is -9.17% below its 200-day SMA.

Current Consensus

VKTX's Technical Analysis Consensus is currently Buy, with 29 buy, 5 neutral, and 12 sell votes. VKTX's 14-day RSI is 54.98, which places the stock in a neutral momentum range. VKTX's beta is 1.29, indicating greater market sensitivity than the broad market.

Signal Confidence
High agreement

What Changed in VKTX?

The largest recent change in VKTX is Momentum moving up by 4.0 points over the available 7-day comparison window. Momentum remains the strongest visible factor.

AIQ Score
+2.0
Momentum
+4.0
Quality
+1.0
Risk
+0.0

What Would Change the VKTX Outlook?

The current bearish outlook could improve if AIQ reaches 65 (Bullish), momentum recovers, earnings revisions strengthen, and price confirms a stronger trend above the 50-day and 200-day moving averages. It would weaken if AIQ falls below 50 (Bearish), price loses long-term moving-average support, analyst expectations deteriorate, or risk evidence worsens.

Bullish confirmation

AIQ 65+ (Bullish), RSI above 55, price above SMA-50/SMA-200, and positive catalyst or estimate-revision evidence.

Bearish deterioration

AIQ below 50 (Bearish), RSI below 45, loss of SMA-200, negative revisions, or rising volatility and drawdown risk.

VKTX Decision Framework

Public evidence layers, setup checks, and risk context for Viking Therapeutics, Inc..

Viking Therapeutics, Inc. (VKTX) Stock Analysis

Viking Therapeutics, Inc. has an AIQ Score of 41/100 in a Bearish regime. Momentum is strongest at 47/100. Beta is 1.29, above market sensitivity. Review the supporting stock factors together before drawing a conclusion from any single score.

Evidence LayerPublic Evidence
Regime ContextVKTX is in a Bearish AIQ regime with score 41/100.
Signal ConflictThe primary conflict is that momentum leads at 47/100 while quality lags at 33/100.
Factor EvidenceMomentum 47/100 · Quality 33/100 · Risk 41/100
PersistenceCurrent snapshot evidence is shown; historical persistence remains in AIQ Pro.

Current Setup Checklist

Factor strengthFail

Momentum is the strongest factor at 47/100.

TimingFail

Momentum is 47/100 and RSI (14) is 55.0.

Regime fitFail

VKTX is in a Bearish regime at 41/100.

Risk controlFail

Risk factor is 41/100 with beta 1.29 and annual volatility 69.18%.

ConflictPass

Current conflict: momentum leads at 47/100 while quality lags at 33/100.

AIQ Score
41/100
Price
$29.22
Beta
1.29
RSI (14)
55

VKTX Research Cluster

Ticker-specific paths for valuation, technical analysis, catalysts, dividends, financials, risk, and news.

VKTX Fundamentals

VKTX valuation, profitability, growth, margins, balance-sheet strength, and free cash flow.

Revenue
$0
Net income
-$183.19M
Free cash flow
-$138.19M
View full VKTX fundamental analysis

VKTX Technical Analysis

VKTX technical setup based on RSI, MACD, moving averages, AIQ Momentum, volume, trend, volatility, and pivots.

Technical Analysis Consensus
Buy
RSI 14
54.98
Price vs SMA-50
-0.36%
View full VKTX technical analysis

VKTX Stock Catalysts

Track VKTX earnings, analyst ratings, price targets, estimate revisions, stock news, and upcoming events.

Next earnings
Feb 10, 2027
Analyst target
$79.67
News items
5
View VKTX earnings and stock catalysts

VKTX Dividend Analysis

VKTX dividend yield, annual dividend, payout ratio, payment history, and income reliability context.

Dividend yield
0.00%
Annual dividend
—
Payout ratio
—
View VKTX dividend history and analysis

VKTX Financial Data

VKTX revenue, earnings, income statement, balance sheet, cash flow, valuation ratios, and stock metrics.

Quarter revenue
$0
EPS
-$1.55
Periods
8
View VKTX financials

VKTX Risk Analysis

VKTX volatility, beta, drawdown, Sharpe ratio, VaR, and downside resilience.

Beta
1.29
Risk score
41/100
1Y volatility
69.18%
View VKTX risk analysis

VKTX Stock News

VKTX stock news, market tone, recent headlines, and catalyst context.

News items
5
Updated
Nov 15, 2026
Sentiment
—
Read VKTX stock news

VKTX vs Biotechnology Peers

Current peer cohort: VKTX · VOR · VRDN · VSTM · XENE. Compare AIQ, factor scores, Sharpe ratio and 1-year volatility in one indexable view.

PeerAIQValueMomentumRiskSharpe1Y VolatilityCompare
VKTX
Current stock
41/100—47/10041/100-0.1569.18%Current
VOR
Vor Biopharma Inc.
66/100—72/10046/1001.1593.53%VKTX vs VOR
VRDN
Viridian Therapeutics, Inc.
58/10037/10091/10046/1000.4371.98%VKTX vs VRDN
VSTM
Verastem, Inc.
60/10053/10089/10036/1000.3274.24%VKTX vs VSTM
XENE
Xenon Pharmaceuticals Inc.
49/100—33/10049/1000.2768.13%VKTX vs XENE
Pairwise Compare links: VOR · VRDN · VSTM · XENEVKTX vs VORVKTX vs VRDNVKTX vs VSTMVKTX vs XENECompare cohort

Peer cohort is resolved dynamically from the AlgovestIQ universe taxonomy and Compare relationship graph. Data as of Nov 13, 2026.

About the AIQ Score

Methodology for the current stock evidence.

As of Nov 13, 2026 · Market close

The AlgovestIQ AIQ Score combines multiple dimensions of stock evidence, including momentum, valuation exposure, quality, risk resilience, sentiment context, and timing signals. It is a descriptive research score, not a guarantee of future performance or a personalized recommendation.

View AIQ methodology

Factor Diagnostics

A compact bridge from the AIQ score to the evidence tabs.

Calculator
Calculate a VKTX stock return scenario

Open the return calculator with stock context while purchase price, shares, dates and fees remain user inputs.

Calculate stock return

Also for VKTX: historical return with reinvested dividends and stock average calculator for several buys.

AIQ Component Profile

Compare the five component scores on one consistent 0–100 scale.

Catalyst preview

Review earnings timing, revisions, news pressure, and prior event reactions in one place.

Open catalysts
Quarterly evidence

8 recent quarterly periods are available for review.

Checked Nov 16, 2026

AIQ Pro

Explore factor drivers, conflicts, persistence, and scenario sensitivity in the advanced workspace.

Fundamentals Verdict

Current snapshot fields are separate from reported-quarter statement tables.

Current TTM P/E
-5.41
As of Nov 13, 2026
Revenue growth
—
Gross margin
0.00%
Current debt / equity
0.43
Latest quarterly evidence

Latest period Sep 30, 2026.

Review fundamentals
Quarter revenue
$0
Quarter net income
-$183.19M
Quarter free cash flow
-$138.19M

Market Confirmation

Technicals are summarized first, with the indicator library behind it.

Trend
Bearish
Momentum
Mixed
RSI 14
54.98
MACD
-0.09

Risk Alignment

Higher resilience is stronger; exposure metrics stay separate.

Resilience
41/100
Beta
1.29
Annual volatility
69.18%
Max drawdown
-42.53%

VKTX Stock FAQ

What is VKTX stock price today?

Viking Therapeutics, Inc.'s current stock price is $29.22. Use the live quote with AIQ Score, news, and risk context rather than treating price alone as a decision signal.

Is VKTX bullish or bearish right now?

VKTX's bullish or bearish read depends on the current AIQ Score, factor alignment, technical analysis consensus, valuation, risk, and catalyst evidence. A mixed setup should be treated differently from a broad confirmation across those signals.

What is VKTX's market cap?

VKTX's market cap is $3.45B based on the latest completed market-close snapshot from Nov 13, 2026. Use it with P/E ratio, revenue, and growth metrics to frame company size, valuation, and peer comparisons.

What is VKTX's current P/E ratio?

VKTX's current P/E ratio is -5.41 based on the latest completed market-close snapshot from Nov 13, 2026. Read it with revenue growth, margins, EPS, cash flow, and peer valuation rather than using P/E alone.

What is VKTX's RSI?

VKTX's 14-day RSI is 54.98 based on the latest completed market-close snapshot from Nov 13, 2026. RSI should be interpreted with MACD, moving averages, volume, volatility, and price trend.

Is VKTX above its 50-day and 200-day moving averages?

VKTX is -0.36% from its 50-day SMA and -9.17% from its 200-day SMA based on the latest completed market-close snapshot from Nov 13, 2026. Moving-average position should be read with momentum and broader AIQ evidence.

When is VKTX's next earnings date?

VKTX's next earnings date is currently listed as Feb 10, 2027. Earnings can reset revenue, EPS, price target, analyst rating, and catalyst expectations.

Does VKTX pay a dividend?

VKTX's dividend yield is 0.00% based on the latest completed market-close snapshot from Nov 13, 2026. Dividend yield should be read with payout ratio, free cash flow, growth, and balance-sheet strength.